These findings suggest that the measurement of one or both of plasma ChT activity and CCL18 concentration in conjunction with assessment of NP-C SI score in patients with suspected NP-C allows better targeting of in-depth confirmatory laboratory tests. The gene discussed is SLC5A7; the disease is nasopharyngeal carcinoma.